FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...

Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer Clonal and subclonal mutations (variant allele frequency ≥5%) in ALK confer inferior prognosis for ...

The Food and Drug Administration (FDA) has granted Fast Track designation to TRI-611 for the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...

Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive ...

Add Yahoo as a preferred source to see more of our stories on Google. The global market for kinase inhibitors targeting ALK-mutated NSCLC is expected to reach $5.7 billion by 2031. Credit: ...

Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment "Our development strategy has been anchored ...

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis. But Yale researchers have identified a subset of those patients with a rare genetic ...